Patents by Inventor Peter Emtage

Peter Emtage has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CHIMERIC TRANSMEMBRANE PROTEINS AND USES THEREOF
    Publication number: 20230416339
    Abstract: Provided herein are chimeric transmembrane proteins and proteins, nucleic acids encoding these chimeric transmembrane proteins or proteins, and mammalian cells containing these nucleic acids, and methods of making and using these mammalian cells.
    Type: Application
    Filed: June 1, 2023
    Publication date: December 28, 2023
    Inventors: Peter Emtage, Gabrielle Romain, Rosa Vincent, Sarah Wyman
  • CD33 specific chimeric antigen receptors
    Patent number: 11787848
    Abstract: Provided herein are chimeric antigen receptors (CARs) for cancer therapy, and more particularly, CARs containing a scFv from a CD33 monoclonal antibody. Provided are immune effector cells containing such CARs, and methods of treating proliferative disorders such as acute myeloid leukemia (AML), and relapsed or refractory AML.
    Type: Grant
    Filed: June 7, 2017
    Date of Patent: October 17, 2023
    Assignee: PRECIGEN, INC.
    Inventors: Rutul Shah, Tim Chan, Peter Emtage, Ramya Yarlagadda
  • Chimeric transmembrane proteins and uses thereof
    Patent number: 11708401
    Abstract: Provided herein are chimeric transmembrane proteins and proteins, nucleic acids encoding these chimeric transmembrane proteins or proteins, and mammalian cells containing these nucleic acids, and methods of making and using these mammalian cells.
    Type: Grant
    Filed: June 21, 2019
    Date of Patent: July 25, 2023
    Assignee: Kite Pharma, Inc.
    Inventors: Peter Emtage, Gabrielle Romain, Rosa Vincent, Sarah Wyman
  • METHODS AND COMPOSITIONS FOR REDUCING THE IMMUNOGENICITY OF CHIMERIC NOTCH RECEPTORS
    Publication number: 20220372090
    Abstract: The present invention relates to methods and compositions for reducing the immunogenicity of chimeric Notch receptors, and specifically to transcription factors useful for controlling gene expression delivered to tissues by such chimeric Notch receptors.
    Type: Application
    Filed: April 8, 2022
    Publication date: November 24, 2022
    Inventors: Peter Emtage, Amy E. Gilbert, Anselm Levskaya, Spencer Scott, Vladimir Anatolievich Slepushkin
  • METHODS AND COMPOSITIONS FOR REDUCING THE IMMUNOGENICITY OF CHIMERIC NOTCH RECEPTORS
    Publication number: 20220363728
    Abstract: The present invention relates to methods and compositions for reducing the immunogenicity of chimeric Notch receptors, and specifically to transcription factors useful for controlling gene expression delivered to tissues by such chimeric Notch receptors.
    Type: Application
    Filed: April 8, 2022
    Publication date: November 17, 2022
    Inventors: Peter Emtage, Amy E. Gilbert, Anselm Levskaya, Spencer Scott, Vladimir Slepushkin
  • Methods and compositions for reducing the immunogenicity of chimeric notch receptors
    Patent number: 11325957
    Abstract: The present invention relates to methods and compositions for reducing the immunogenicity of chimeric Notch receptors, and specifically to transcription factors useful for controlling gene expression delivered to tissues by such chimeric Notch receptors.
    Type: Grant
    Filed: June 18, 2018
    Date of Patent: May 10, 2022
    Assignee: Cell Design Labs, Inc.
    Inventors: Amy Gilbert, Vladimir Slepushkin, Peter Emtage, Anselm Levskaya, Spencer Scott
  • EXPRESSION OF NOVEL CELL TAGS
    Publication number: 20220064609
    Abstract: Disclosed herein are polynucleotides encoding cell tags for use in immunotherapeutic applications, and systems comprising polynucleotide cell tags for regulating the activity of a cell. The compositions, methods and systems described herein provide tools for regulating activity of genetically engineered cells in a subject.
    Type: Application
    Filed: June 11, 2021
    Publication date: March 3, 2022
    Applicant: PRECIGEN, INC.
    Inventors: Rutul SHAH, Peter EMTAGE, Ramya YARLAGADDA
  • IMMUNE CELL FUNCTION
    Publication number: 20220047677
    Abstract: The present disclosure relates to the field of cell therapy, and more specifically, to improving CAR and/or TCR function through improvement of the tumor microenvironment via improvement in cytokine signaling.
    Type: Application
    Filed: August 12, 2021
    Publication date: February 17, 2022
    Inventors: Peter Emtage, Jun Feng, Heba Nowyhed, Tammy Phung
  • CHIMERIC POLYPEPTIDES AND METHODS OF ALTERING THE MEMBRANE LOCALIZATION OF THE SAME
    Publication number: 20210395386
    Abstract: Methods and compositions are provided for reversibly localizing proteins to the exterior part of the cell surface. Compositions provided herein can include nucleic acids that encode polypeptides of interest and the ligand binding domain (LBD) of a nuclear hormone receptor. Medical applications are provided, including controlling the toxicity of CAR T cells.
    Type: Application
    Filed: August 13, 2021
    Publication date: December 23, 2021
    Inventors: Stephen Santoro, Scott Coyle, Levi Rupp, Peter Emtage
  • EXPRESSION OF NOVEL CELL TAGS
    Publication number: 20210324350
    Abstract: Disclosed herein are polynucleotides encoding cell tags for use in immunotherapeutic applications, and systems comprising polynucleotide cell tags for regulating the activity of a cell. The compositions, methods and systems described herein provide tools for regulating activity of genetically engineered cells in a subject.
    Type: Application
    Filed: May 5, 2021
    Publication date: October 21, 2021
    Applicant: PRECIGEN, INC.
    Inventors: Rutul SHAH, Peter EMTAGE, Ramya YARLAGADDA
  • Expression of novel cell tags
    Patent number: 11118168
    Abstract: Disclosed herein are polynucleotides encoding cell tags for use in immunotherapeutic applications, and systems comprising polynucleotide cell tags for regulating the activity of a cell. The compositions, methods and systems described herein provide tools for regulating activity of genetically engineered cells in a subject.
    Type: Grant
    Filed: June 6, 2018
    Date of Patent: September 14, 2021
    Assignee: PRECIGEN, INC.
    Inventors: Rutul Shah, Peter Emtage, Ramya Yarlagadda
  • Chimeric polypeptides and methods of altering the membrane localization of the same
    Patent number: 11111310
    Abstract: Methods and compositions are provided for reversibly localizing proteins to the exterior part of the cell surface. Compositions provided herein can include nucleic acids that encode polypeptides of interest and the ligand binding domain (LBD) of a nuclear hormone receptor. Medical applications are provided, including controlling the toxicity of CAR T cells.
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: September 7, 2021
    Assignee: Cell Design Labs, Inc.
    Inventors: Stephen Santoro, Scott Coyle, Levi Rupp, Peter Emtage
  • CD40L-Fc FUSION POLYPEPTIDES AND METHODS OF USE THEREOF
    Publication number: 20210260159
    Abstract: Provided herein is a CD40L-Fc fusion protein and methods of using the fusion protein in the treatment of cancer comprising administering the CD40L-Fc fusion protein or the CD40L-Fc fusion protein in combination with one or more immune checkpoint inhibitors (e.g., an anti-CTLA4 antibody, anti-PD-L1 antibody).
    Type: Application
    Filed: March 8, 2021
    Publication date: August 26, 2021
    Inventors: MANUEL BACA, STACEY DRABIC, PETER EMTAGE, RONALD HERBST
  • Expression of novel cell tags
    Patent number: 11034940
    Abstract: Disclosed herein are polynucleotides encoding cell tags for use in immunotherapeutic applications, and systems comprising polynucleotide cell tags for regulating the activity of a cell. The compositions, methods and systems described herein provide tools for regulating activity of genetically engineered cells in a subject.
    Type: Grant
    Filed: June 6, 2018
    Date of Patent: June 15, 2021
    Assignee: PRECIGEN, INC.
    Inventors: Rutul Shah, Peter Emtage, Ramya Yarlagadda
  • CD40L-Fc fusion polypeptides and methods of use thereof
    Patent number: 10975155
    Abstract: Provided herein is a CD40L-Fc fusion protein and methods of using the fusion protein in the treatment of cancer comprising administering the CD40L-Fc fusion protein or the CD40L-Fc fusion protein in combination with one or more immune checkpoint inhibitors (e.g., an anti-CTLA4 antibody, anti-PD-L1 antibody).
    Type: Grant
    Filed: May 12, 2017
    Date of Patent: April 13, 2021
    Assignee: MEDIMMUNE, LLC
    Inventors: Manuel Baca, Stacey Drabic, Peter Emtage, Ronald Herbst
  • CHIMERIC TRANSMEMBRANE PROTEINS AND USES THEREOF
    Publication number: 20210015864
    Abstract: Provided herein are chimeric transmembrane proteins, nucleic acids encoding these chimeric transmembrane proteins, and mammalian cells containing these nucleic acids, and methods of making and using these mammalian cells.
    Type: Application
    Filed: March 21, 2019
    Publication date: January 21, 2021
    Inventors: Peter Emtage, Rosa Vincent
  • TGF-beta Receptors and Methods of Use
    Publication number: 20200397823
    Abstract: Provided herein are engineered receptors involved in cytokine signaling. Also provided herein are engineered receptors for modulating TGF-? signaling, methods of modulating TGF-? signaling and treating cancer using chimeric antigen receptors.
    Type: Application
    Filed: June 19, 2020
    Publication date: December 24, 2020
    Inventors: Sarah WYMAN, Peter EMTAGE, Gabrielle ROMAIN
  • CHIMERIC TRANSMEMBRANE RECEPTORS AND USES THEREOF
    Publication number: 20200384030
    Abstract: Provided herein are chimeric transmembrane receptors and methods of using them to regulate selective gene expression in cells (e.g., immune cells). For example, chimeric transmembrane receptors provided herein may be synthetic receptor-like protein tyrosine phosphatases (“synPTPRs”) that can regulate transcription of a heterologous target gene in a cell when bound by a target antigen present on a target cell.
    Type: Application
    Filed: February 20, 2019
    Publication date: December 10, 2020
    Inventors: Peter Emtage, Andrew Glibicky, Spencer Scott
  • CHIMERIC TRANSMEMBRANE PROTEINS AND USES THEREOF
    Publication number: 20200002402
    Abstract: Provided herein are chimeric transmembrane proteins and proteins, nucleic acids encoding these chimeric transmembrane proteins or proteins, and mammalian cells containing these nucleic acids, and methods of making and using these mammalian cells.
    Type: Application
    Filed: June 21, 2019
    Publication date: January 2, 2020
    Inventors: Peter Emtage, Gabrielle Romain, Rosa Vincent, Sarah Wyman
  • SINGLE- AND MULTI-CHAIN CHIMERIC ANTIGEN RECEPTORS
    Publication number: 20190194617
    Abstract: Provided herein are single-chain and multi-chain chimeric antigen receptors, nucleic acids encoding the same, and mammalian cells expressing the same. Also provided are methods of treating a cancer in a subject using a mammalian cell expressing any of these single-chain and multi-chain chimeric antigen receptors.
    Type: Application
    Filed: December 19, 2018
    Publication date: June 27, 2019
    Inventors: Peter Emtage, Sarah Wyman